ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Insmed Initiates ARIKAYCE Trial for MAC Lung Disease
January 11, 2021Insmed announced the first patient was dosed in the frontline clinical trial program of ARIKAYCE® (amikacin liposome inhalation suspension) in patients with nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC). -
Insmed Receives FDA Breakthrough Therapy Designation for Non-Cystic Fibrosis Bronchiectasis Treatment
June 17, 2020Insmed announced the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation for brensocatib (formerly known as INS1007) for the treatment of adult patients with non-cystic fibrosis bronchiectasis (NCFBE) for reducing ... -
Insmed Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
February 24, 2019Insmed Incorporated a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2018 and provided a business u -
Insmed appoints Leo Lee to its Board of Directors
May 21, 2018Lee has more than 21 years of experience in the pharmaceutical industry in Japan.
Pharma Sources Insight January 2025
